ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 68 filers reported holding ADC THERAPEUTICS SA in Q3 2022. The put-call ratio across all filers is 2.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $595,632 | -57.6% | 664,027 | +1.7% | 0.00% | – |
| Q2 2023 | $1,403,473 | +64.3% | 652,778 | +49.1% | 0.00% | – |
| Q1 2023 | $854,001 | -36.6% | 437,949 | +24.9% | 0.00% | – |
| Q4 2022 | $1,346,968 | -1.3% | 350,773 | +23.9% | 0.00% | – |
| Q3 2022 | $1,365,000 | -16.5% | 283,012 | +37.7% | 0.00% | – |
| Q2 2022 | $1,634,000 | +29.6% | 205,568 | +139.4% | 0.00% | – |
| Q1 2022 | $1,261,000 | -11.9% | 85,865 | +21.2% | 0.00% | – |
| Q4 2021 | $1,431,000 | -37.9% | 70,843 | -16.5% | 0.00% | – |
| Q3 2021 | $2,304,000 | -62.1% | 84,857 | -66.0% | 0.00% | -100.0% |
| Q2 2021 | $6,075,000 | +21.9% | 249,527 | +22.2% | 0.00% | 0.0% |
| Q1 2021 | $4,985,000 | +41.8% | 204,227 | +86.0% | 0.00% | 0.0% |
| Q4 2020 | $3,515,000 | +915.9% | 109,811 | +946.7% | 0.00% | – |
| Q3 2020 | $346,000 | -41.3% | 10,491 | -16.6% | 0.00% | – |
| Q2 2020 | $589,000 | – | 12,585 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,680,149 | $24,681,000 | 9.63% |
| Grosvenor Holdings, L.L.C. | 1,517,212 | $22,288,000 | 4.35% |
| Redmile Group, LLC | 7,432,429 | $109,182,000 | 3.41% |
| MPM BioImpact LLC | 334,384 | $4,912,000 | 1.32% |
| Indie Asset Partners, LLC | 96,572 | $1,419,000 | 1.07% |
| Eventide Asset Management | 1,975,000 | $29,013,000 | 0.46% |
| HHLR ADVISORS, LTD. | 500,000 | $7,345,000 | 0.15% |
| Virtus ETF Advisers LLC | 19,193 | $282,000 | 0.13% |
| Walleye Capital LLC | 248,354 | $3,648,000 | 0.10% |
| Matrix Capital Management Company, LP | 400,000 | $5,876,000 | 0.07% |